Literature DB >> 12604527

Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei.

Chiatogu Onyewu1, Jill R Blankenship, Maurizio Del Poeta, Joseph Heitman.   

Abstract

Azoles target the ergosterol biosynthetic enzyme lanosterol 14alpha-demethylase and are a widely applied class of antifungal agents because of their broad therapeutic window, wide spectrum of activity, and low toxicity. Unfortunately, azoles are generally fungistatic and resistance to fluconazole is emerging in several fungal pathogens. We recently established that the protein phosphatase calcineurin allows survival of Candida albicans during the membrane stress exerted by azoles. The calcineurin inhibitors cyclosporine A (CsA) and tacrolimus (FK506) are dramatically synergistic with azoles, resulting in potent fungicidal activity, and mutant strains lacking calcineurin are markedly hypersensitive to azoles. Here we establish that drugs targeting other enzymes in the ergosterol biosynthetic pathway (terbinafine and fenpropimorph) also exhibit dramatic synergistic antifungal activity against wild-type C. albicans when used in conjunction with CsA and FK506. Similarly, C. albicans mutant strains lacking calcineurin B are markedly hypersensitive to terbinafine and fenpropimorph. The FK506 binding protein FKBP12 is required for FK506 synergism with ergosterol biosynthesis inhibitors, and a calcineurin mutation that confers FK506 resistance abolishes drug synergism. Additionally, we provide evidence of drug synergy between the nonimmunosuppressive FK506 analog L-685,818 and fenpropimorph or terbinafine against wild-type C. albicans. These drug combinations also exert synergistic effects against two other Candida species, C. glabrata and C. krusei, which are known for intrinsic or rapidly acquired resistance to azoles. These studies demonstrate that the activity of non-azole antifungal agents that target ergosterol biosynthesis can be enhanced by inhibition of the calcineurin signaling pathway, extending their spectrum of action and providing an alternative approach by which to overcome antifungal drug resistance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12604527      PMCID: PMC149324          DOI: 10.1128/AAC.47.3.956-964.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  41 in total

Review 1.  Infectious complications of solid organ transplantations.

Authors:  D M Simon; S Levin
Journal:  Infect Dis Clin North Am       Date:  2001-06       Impact factor: 5.982

Review 2.  Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis.

Authors:  Paul Nghiem; Greg Pearson; Richard G Langley
Journal:  J Am Acad Dermatol       Date:  2002-02       Impact factor: 11.527

3.  Calcineurin is essential for survival during membrane stress in Candida albicans.

Authors:  M Cristina Cruz; Alan L Goldstein; Jill R Blankenship; Maurizio Del Poeta; Dana Davis; Maria E Cardenas; John R Perfect; John H McCusker; Joseph Heitman
Journal:  EMBO J       Date:  2002-02-15       Impact factor: 11.598

4.  Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada.

Authors:  G St-Germain; M Laverdière; R Pelletier; A M Bourgault; M Libman; C Lemieux; G Noël
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

5.  Anti-fungal therapy at the HAART of viral therapy.

Authors:  Carol A Munro; Bernhard Hube
Journal:  Trends Microbiol       Date:  2002-04       Impact factor: 17.079

6.  Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major.

Authors:  Abdulrahman A Alrajhi; Elfaki A Ibrahim; Edward B De Vol; Mohammad Khairat; Rajab M Faris; James H Maguire
Journal:  N Engl J Med       Date:  2002-03-21       Impact factor: 91.245

7.  Fluconazole plus cyclosporine: a fungicidal combination effective against experimental endocarditis due to Candida albicans.

Authors:  O Marchetti; J M Entenza; D Sanglard; J Bille; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

8.  Candida albicans sterol C-14 reductase, encoded by the ERG24 gene, as a potential antifungal target site.

Authors:  N Jia; B Arthington-Skaggs; W Lee; C A Pierson; N D Lees; J Eckstein; R Barbuch; M Bard
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

9.  Rapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of TOR.

Authors:  M C Cruz; A L Goldstein; J Blankenship; M Del Poeta; J R Perfect; J H McCusker; Y L Bennani; M E Cardenas; J Heitman
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

Review 10.  Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome.

Authors:  S Husain; M M Wagener; N Singh
Journal:  Emerg Infect Dis       Date:  2001 May-Jun       Impact factor: 6.883

View more
  97 in total

1.  Miconazole induces fungistasis and increases killing of Candida albicans subjected to photodynamic therapy.

Authors:  Sara B Snell; Thomas H Foster; Constantine G Haidaris
Journal:  Photochem Photobiol       Date:  2011-12-20       Impact factor: 3.421

Review 2.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

3.  Functional assignment of YvgO, a novel set of purified and chemically characterized proteinaceous antifungal variants produced by Bacillus thuringiensis SF361.

Authors:  David C Manns; John J Churey; Randy W Worobo
Journal:  Appl Environ Microbiol       Date:  2012-02-03       Impact factor: 4.792

4.  The Rho1 GTPase-activating protein CgBem2 is required for survival of azole stress in Candida glabrata.

Authors:  Sapan Borah; Raju Shivarathri; Rupinder Kaur
Journal:  J Biol Chem       Date:  2011-08-08       Impact factor: 5.157

5.  The Rim Pathway Mediates Antifungal Tolerance in Candida albicans through Newly Identified Rim101 Transcriptional Targets, Including Hsp90 and Ipt1.

Authors:  Cécile Garnaud; Encar García-Oliver; Yan Wang; Danièle Maubon; Sébastien Bailly; Quentin Despinasse; Morgane Champleboux; Jérôme Govin; Muriel Cornet
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

6.  In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients.

Authors:  William J Steinbach; Nina Singh; Jackie L Miller; Daniel K Benjamin; Wiley A Schell; Joseph Heitman; John R Perfect
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

7.  Calcineurin is required for Candida albicans to survive calcium stress in serum.

Authors:  Jill R Blankenship; Joseph Heitman
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

Review 8.  Activation of stress signalling pathways enhances tolerance of fungi to chemical fungicides and antifungal proteins.

Authors:  Brigitte M E Hayes; Marilyn A Anderson; Ana Traven; Nicole L van der Weerden; Mark R Bleackley
Journal:  Cell Mol Life Sci       Date:  2014-02-14       Impact factor: 9.261

Review 9.  Challenges in the Polyene- and Azole-Based Pharmacotherapy of Ocular Fungal Infections.

Authors:  Prit Lakhani; Akash Patil; Soumyajit Majumdar
Journal:  J Ocul Pharmacol Ther       Date:  2018-11-08       Impact factor: 2.671

Review 10.  Signaling cascades as drug targets in model and pathogenic fungi.

Authors:  Robert J Bastidas; Jennifer L Reedy; Helena Morales-Johansson; Joseph Heitman; Maria E Cardenas
Journal:  Curr Opin Investig Drugs       Date:  2008-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.